Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE VC W CODEINE versus TRIPROLIDINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE VC W CODEINE versus TRIPROLIDINE HYDROCHLORIDE.
PROMETHAZINE VC W/ CODEINE vs TRIPROLIDINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug converted to morphine, which acts as a mu-opioid receptor agonist inhibiting ascending pain pathways and altering pain perception. Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, suppresses cough reflex via central action, and has anticholinergic, sedative, and antiemetic effects. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction of nasal blood vessels, reducing congestion.
Competitive antagonist of histamine H1 receptors; inhibits histamine-mediated vasodilation, increased capillary permeability, and bronchoconstriction in allergic reactions.
1-2 tablets orally every 4-6 hours as needed for cough and congestion. Maximum 12 tablets in 24 hours.
2.5 mg orally every 4-6 hours as needed; maximum 10 mg per 24 hours.
None Documented
None Documented
Promethazine: 9-16 hours (range 7-20 hours) in adults; codeine: 2.5-3.5 hours (terminal) with clinical considerations for prolonged effects in hepatic impairment and CYP2D6 poor metabolizers.
Terminal elimination half-life approximately 3–4 hours in healthy adults; prolonged in renal impairment (up to 12 hours).
Renal: 70-80% as unchanged promethazine and metabolites (including codeine and its glucuronides); biliary/fecal: 10-20%.
Renal (primarily as metabolites; ~70% recovered in urine within 24 hours, <5% unchanged). Fecal elimination is minor.
Category A/B
Category A/B
Antihistamine / Antiemetic
Antihistamine